Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementi… (NCT07114354) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementia in Parkinson's Disease
275 participantsStarted 2025-08-18
Plain-language summary
Dementia is observed in 80% of people living with advanced stage Parkinson's disease, however, there are inadequate opportunities for early and effective diagnosis of dementia in current clinical practice. This study aims to identify whether a new tool called PDCogniCare, can improve detection of dementia in people living with Parkinson's disease, and to explore what factors might influence its use in healthcare services.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* People living with idiopathic Parkinson's disease, one year or more post-diagnosis, attending Movement Disorder Clinics
Exclusion Criteria:
* People with severe Parkinson's disease who aren't able to communicate
* People with comorbid neurological conditions (e.g. Stroke)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is focused on improving how dementia is diagnosed in people with Parkinson's disease — given my current stage of Parkinson's, does my doctor think I would be an appropriate candidate to discuss when this study opens for enrollment?
2Since this trial is listed as 'not yet recruiting,' how long might it realistically be before it starts, and should I be pursuing other memory or cognitive evaluations in the meantime?
3The trial is measuring changes in how many Parkinson's patients get diagnosed with dementia, which sounds like it's about improving diagnostic tools rather than testing a treatment — can my doctor explain what that would actually mean for me day-to-day if I participated?
4Because this study is Phase NA, meaning it's not a standard drug or device trial, what kind of procedures or assessments would I likely go through, and are there any risks or burdens I should weigh against participating?
5If the goal is earlier and more accurate dementia diagnosis in Parkinson's disease, should I be asking about neuropsychological testing now through my regular care, rather than waiting for this trial to begin?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in percentage of people with Parkinson's disease diagnosed with dementia